title: Chronic actinic dermatitis treated with mycophenolate mofetil.
abstract: Chronic actinic dermatitis (CAD) is a persistent photodermatosis that usually affects elderly men. We report two male patients, aged 55 years (patient A) and 49 years (patient B), who presented with an eczematous eruption on sun-exposed skin. Phototesting revealed a markedly reduced 24-h minimal erythema dose (MED). Both patients had refractory disease and developed significant side-effects to conventional therapies, including topical steroids, prednisolone, psoralen with ultraviolet A, azathioprine and ciclosporin. They had each received at least 6 years of treatment prior to commencing mycophenolate mofetil (MMF). Each noted a significant improvement in symptoms within 6 weeks and subsequent clearing of the eczematous lesions. Patient A still requires continuous treatment with MMF 500 mg twice daily to prevent relapses. Patient B maintains remission by using MMF 1 g twice daily only during the spring and summer months. Both patients have tolerated the treatment well with no abnormalities in blood cell counts or liver biochemistry. Since commencing MMF, their quality of life has significantly improved. These observations suggests that MMF should be considered as an alternative treatment to conventional therapies for refractory CAD.
authors.affiliation: Department of Dermatology, Selly Oak Hospital, University of Birmingham NHS Trust, Birmingham, B29 6JD, UK. michelle.thomson@uhcw.nhs.uk
authors.forename: M A
authors.initials: MA
authors.lastname: Thomson
authors.forename: D G
authors.initials: DG
authors.lastname: Stewart
authors.forename: H M
authors.initials: HM
authors.lastname: Lewis
mesh_terms: D002908:Chronic Disease; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005148:Facial Dermatoses / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010787:Photosensitivity Disorders / Q000188:drug therapy* / Q000517:prevention & control; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid